Gonapeptyl

Gonapeptyl is a prescription injectable medication that contains the synthetic peptide triptorelin acetate as its active ingredient. It is supplied as a solution for subcutaneous administration. As a gonadotropin‑releasing hormone (GnRH) agonist, Gonapeptyl initially stimulates then suppresses pituitary release of luteinising hormone (LH) and follicle‑stimulating hormone (FSH). It is marketed in the European Union and is used under the guidance of healthcare professionals in clinical practice.

Gonapeptyl is indicated for several hormone‑dependent conditions where suppression of gonadotropins is required.

- Advanced prostate cancer: provides medical castration by lowering testosterone levels. - Endometriosis: alleviates pelvic pain and limits lesion growth through estrogen suppression. - Uterine fibroids: decreases fibroid volume and menstrual bleeding by reducing ovarian hormone production. - Central precocious puberty: delays further sexual development by inhibiting pituitary gonadotropin release. - Assisted reproductive technology: controls timing of follicular development during in‑vitro fertilisation cycles. - Hormone‑sensitive tumours: used as part of a multidisciplinary approach to reduce tumour‑stimulating hormones. - Palliative care: may be employed to manage hormone‑related symptoms in certain malignancies.

The pharmacologic action of Gonapeptyl can produce a range of adverse effects, most of which are related to the rapid decline in sex hormones.

Common: - Hot flashes, sweating, and transient headache. - Decreased libido or erectile dysfunction in men. - Irregular menstrual bleeding or amenorrhea in women. - Injection site reactions such as mild pain or erythema. - Mood changes including depression or anxiety. - Nausea or gastrointestinal discomfort.

Serious: - Bone mineral density loss leading to osteoporosis with long‑term use. - Cardiovascular events including hypertension or thromboembolic disorders. - Severe allergic reactions such as anaphylaxis or angio‑edema. - Pituitary apoplexy (rare) due to abrupt hormonal shifts.

Before initiating Gonapeptyl therapy, clinicians should evaluate several patient‑specific factors to minimise risks and ensure appropriate use.

- Assess cardiovascular risk, especially in patients with hypertension or a history of thromboembolism. - Evaluate bone health; consider calcium and vitamin D supplementation for long‑term treatment. - Review liver and renal function, as dose adjustments may be needed in severe impairment. - Screen for hypersensitivity to triptorelin acetate or any formulation components. - Discuss potential impact on fertility and the need for contraceptive measures during treatment. - Monitor growth and development in children receiving therapy for precocious puberty. - Consider psychological effects; provide counseling for mood changes or depressive symptoms.

Gonapeptyl may alter the pharmacodynamics or pharmacokinetics of other medicines; certain combinations should be avoided or used with close monitoring.

Avoid: - Concurrent use with other GnRH agonists or antagonists, which can cause excessive hormonal suppression. - Strong estrogen‑containing therapies that counteract the intended hypo‑estrogenic effect. - Medications known to prolong the QT interval, increasing cardiac risk when combined with Gonapeptyl.

Use with caution: - Anticoagulants, because injection site bleeding may be enhanced. - Corticosteroids, as they may affect bone density when combined with long‑term Gonapeptyl. - Chemotherapeutic agents, requiring coordination to manage overlapping side‑effect profiles. - Hormone replacement therapy, which may need dose adjustment to maintain desired hormonal levels.